MedTrace Logo

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

NCT02665065 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2023-07-19

No results posted yet for this study

Summary

The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).

Conditions

  • Acute Myeloid Leukemia
  • Leukemia, Acute Myeloid
  • Myeloid Leukemia, Acute
  • Leukemia, Myeloid, Acute
  • Acute Myelogenous Leukemia
  • Leukemia, Acute Myelogenous
  • Myelogenous Leukemia, Acute
  • AML
  • Bone Marrow Transplant

Interventions

DRUG

Iomab-B

DRUG

Conventional Care

PROCEDURE

HCT

Sponsors & Collaborators

  • Actinium Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Avinash Desai, MD · Actinium Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2022-06-30
Completion
2026-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02665065 on ClinicalTrials.gov